Amryt Pharma Holdings Ltd (NASDAQ:AMYT) – Cantor Fitzgerald issued their FY2020 EPS estimates for shares of Amryt Pharma in a research note issued to investors on Thursday, July 9th. Cantor Fitzgerald analyst B. Folkes forecasts that the company will earn ($2.70) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $45.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Amryt Pharma’s FY2021 earnings at ($1.50) EPS.

Shares of AMYT stock opened at $11.08 on Monday. Amryt Pharma has a 12-month low of $10.24 and a 12-month high of $15.50.

Amryt Pharma Company Profile

There is no company description available for Amryt Pharma Holdings Ltd.

Recommended Story: Resistance Level

Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with's FREE daily email newsletter.